News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cerus Corporation (CERS) to Partner With American Red Cross and Blood Systems to Commercialize INTERCEPT Plasma for Thrombotic Thrombocytopenic Purpura (TTP) Orphan Indication


9/11/2012 9:48:48 AM

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that it has entered into independent partnership agreements with both the American Red Cross and Blood Systems Incorporated (BSI) to commercialize INTERCEPT plasma for use in the orphan indication of thrombotic thrombocytopenic purpura (TTP) in the United States.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES